Valuation: Impax Laboratories Inc

Market Cap 5.52B 4.83B 4.46B 4.16B 7.84B 521B 8.02B 53.65B 20.71B 257B 20.71B 20.26B 893B P/E 2026 *
50.5x
P/E 2027 * 21.3x
Enterprise Value 7.8B 6.83B 6.3B 5.89B 11.08B 737B 11.33B 75.85B 29.28B 364B 29.28B 28.64B 1,263B EV / Sales 2026 *
2.51x
EV / Sales 2027 * 2.2x
Free-Float
52.02%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 31/07/2019
Chief Executive Officer 54 31/07/2019
Director of Finance/CFO 58 06/11/2023
Director TitleAgeSince
Director/Board Member 59 06/11/2023
Director/Board Member 70 06/11/2023
Director/Board Member 52 06/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-2.92% - - 5.5B
+1.81%+11.60%+58.61%+164.79% 1,077B
+1.51%+11.77%+69.61%+57.53% 613B
+0.38%+10.56%+39.49%+90.88% 448B
+0.99%+5.24%+28.17%+22.73% 332B
-0.14%+7.58%+39.85%+27.25% 293B
-0.06%+4.92%+31.21%+41.59% 286B
-0.96%+4.98%-28.02%-40.96% 215B
+0.62%+4.59%+30.10%+63.03% 193B
-1.21%+1.17%+14.15%+66.20% 159B
Average -0.06%+7.46%+31.46%+54.78% 401.79B
Weighted average by Cap. +0.65%+9.11%+43.00%+81.53%

Financials

2026 *2027 *
Net sales 3.11B 2.72B 2.51B 2.34B 4.41B 294B 4.51B 30.21B 11.66B 145B 11.66B 11.41B 503B 3.33B 2.92B 2.69B 2.51B 4.73B 315B 4.84B 32.39B 12.5B 155B 12.5B 12.23B 539B
Net income 113M 98.67M 91.09M 85.06M 160M 10.65B 164M 1.1B 423M 5.26B 423M 414M 18.25B 270M 236M 218M 204M 383M 25.49B 392M 2.62B 1.01B 12.58B 1.01B 990M 43.66B
Net Debt 2.28B 2B 1.84B 1.72B 3.24B 216B 3.32B 22.2B 8.57B 106B 8.57B 8.38B 370B 1.8B 1.57B 1.45B 1.36B 2.56B 170B 2.61B 17.49B 6.75B 83.88B 6.75B 6.61B 291B
Logo Impax Laboratories Inc
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-